title: [New targets in pharmacotherapy of type 2 diabetes].
abstract: The number of people with diabetes is expected to increase worldwide to 360 million within the next 15 years of which 90% will have type 2 diabetes (non-insulin-dependent diabetes mellitus). Established therapies mainly focus on the following principles: increase in plasma insulin, improving insulin sensitivity of tissues, reducing the rate of carbohydrate absorption and gluconeogenesis. The demand on compounds with new mechanisms of action is obvious. This articles summarizes new targets and compounds under development for pharmacotherapy of typ 2 diabetes; at present approx. 180 compounds are going to be developed worldwide.
authors.forename: Eugen J
authors.initials: EJ
authors.lastname: Verspohl
mesh_terms: D003924:Diabetes Mellitus, Type 2 / Q000188:drug therapy*; D006801:Humans; D007004:Hypoglycemic Agents / Q000627:therapeutic use*; D007328:Insulin / Q000627:therapeutic use; D007333:Insulin Resistance
chemical_list: D007004:Hypoglycemic Agents; D007328:Insulin